The expression of genes of the anti-apoptotic Bcl-2 family is particularly varied in T-ALL patients; therefore, inhibitors targeting proteins encoded by these genes have variable effects on the various T-ALL cell lines [106]. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.